This site is intended only for Australian Healthcare Professionals

Search

Menu

Close

Sign In or RegisterLog Out Pfizer medicinesExplore contentExplore contentEventsVideosMaterialsLet’s connectLet's ConnectContact usAsk a questionPfizer Medical InformationStay connectedSuggest a topicPharmacy HubmyCPDPAVE

Menu

Close

About JAKi Experience  JAKi Market Experience XELJANZ Mechanism of Action Efficacy and Safety Clinical Efficacy RA Rapid Data (ACR20) Head-to-Head Noninferiority Data (ACR50) Clinical Efficacy PsA ACR20 Data PASI75 Data Enthesitis and Dactylitis Data Clinical Efficacy UC 8-Week Efficacy Onset of Action Data 52-Week Efficacy OCTAVE Study Design Safety and Tolerability Safety in RA Safety in PsA Safety in UC Dosing and Administration Dosing in RA Dosing Practical Considerations Dosing in PsA Dosing Practical Considerations Dosing in UC Dosing Practical Considerations Resources and Support Resources and Support eXel ProgramEventsMaterials Videos
Safety in RA, including ORAL Surveillance postmarketing data​​​​​​​Safety profile from the RA clinical trial programs2
Scroll left to view table

Most common adverse reactions in the first
3 months of 2 phase II and 5 phase III clinical trials2,a
  XELJANZ® 5 mg BID
(n=1336)  		 Placebo
(n=809)  
Upper respiratory tract infection 4% 3%
Headache 4% 2%
Diarrhea 4% 2%
Nasopharyngitis 4% 3%
Scroll left to view table
Adverse events (AEs)[all-cause] and serious adverse events (SAEs) in patients receiving XELJANZ over more than 9 years3
  All XELJANZb (n=4481) 16,291 pt-yrs XELJANZ 5 mg BID (n=1123) 4683 pt-yrs
Patients with AEs (any cause), n (%) 4036 (90.1) 1015 (90.4)
Discontinuation due to AEs, n (%) 1120 (25.0) 315 (28.0)
SAEs, patients with events/100 pt-yrs (95% CI) 9.0 (8.6, 9.5) 8.2 (7.3, 9.1)
Limitations of pooled and long-term extension (LTE) data4
  • Pooled, post hoc analysis of studies from the RA clinical trial program are subject to certain limitations. First, unlike ORAL Surveillance, the patient population is not limited to a high-risk population but includes all enrolled patients. Second, endpoints of interest (such as MACE and malignancy for ORAL Surveillance) were not all specifically defined or adjudicated. Additionally, ORAL Surveillance was a long-term safety study (vs RCT phase 3 which are short term and designed to test efficacy). Resultant incidence rates in ORAL Surveillance differed from rates seen from pooled study data, suggesting the pooled data may be obscuring information about predictors of events given adverse rates may differ from one patient population to another and may change over time
  • ​​​​​​​LTE studies may provide useful data, however, conduct of open-label LTE studies where both treatment and dose are known to both investigator and patient is subject to certain biases and limitations. Most participants were known to have responded to, and tolerated, XELJANZ® (all had completed a qualifying study), hence our findings might not be generalizable to patients new to XELJANZ
  • ​​​​​​​Biases include, but are not limited to, patient selection (patient willingness or ineligibility to enroll, which may be due to a prior serious AE), prior treatment, volunteer, observer, initial dose or study drug, investigator/patient expectation and study duration. Limitations include, but are not limited to, AE frequencies and incidence rates subject to change over time due to patient entry/exit, dose changes influenced by both investigator and patient, dose restrictions in certain countries, the number of patients and exposure for a specific safety event possibly differing depending on the timing of censored events, and the number of observed patients with longer exposure times becoming lower
Integrated safety summary (ISS): baseline characteristics and demographics5
Scroll left to view table

Characteristics RA | All XELJANZ® Dosesa,b
(N=7964)
Mean age, years 52.6
≥65 at baseline, n (%) 1270 (15.9)
Female, n (%) 6522 (81.9)
BMI (kg/m2), mean 27.1
Disease duration (years), mean (range) 8.1 (0.00-65.7)
CRP (mg/L). median (Q1-Q3) 9.2 (3.8-22.8)
Current/ past smokers, n (%) 2754 (34.6)
Prior therapy. n (%)
    Methotrexate 6657 (83.6)
    Non-bDMARD(non-methotrexate) 3739 (46.9)
    TNFi 1245 (15.6)
    Non-TNFi bDMARD 414 (5.2)
Concomitant corticosteroids, n (%) 4254 (53.4)
Scroll left to view table
Incidence rates, patients with events/100 pt-yrs (95% CI) for safety events of interest5,6,c
  RA | All XELJANZ® Dosesb,c
(N=7964) 23,497 pt-yrs
Serious infections 2.5 (2.3, 2.7)
HZ (nonserious and serious) 3.6 (3.3, 3.8)
TBf 0.2 (0.1, 0.2)
Opportunistic infections (excluding TB)f 0.4 (0.3, 05)
Malignancies (excluding NMSC)f 0.7 (06, 0.9)
NMSCf 0.6 (0.5, 0.7)
Lymphoma/lymphoproliferative disordersf 0.1 (0.0, 0.1)
MACEf,g 0.4 (0.3, 0.5)
VTE 0.25 (0.19, 0.33)
DVT 0.2 (0.1, 0.2)
PE 0.1 (0.1, 0.2)
ATE 0.35 (0.28, 0.44)
Gastrointestinal perforationf 0.1 (0.1, 0.2)
  • The ISS and analysis of adverse events of special interest includes pooled data from patients exposed to ≥1 dose of XELJANZ in phase 1, 2, 3, or 3b/4 clinical trials, and LTE studies in RA5
  • In LTE studies, dose adjustments for XELJANZ or concomitant medications were allowed at the investigator’s discretion for efficacy or safety reasons5
Adverse reactions occurring in ≥2% of patients receiving XELJANZ 5 mg BID and ≥1% greater than that observed in patients on placebo (XELJANZ 5 mg BID and placebo ± csDMARDs).Includes XELJANZ 5 mg BID and 10 mg BID treatment arms ± csDMARDs; XELJANZ 5 mg BID is the approved dose in Australia.2Final data for the RA cohorts are from April 18, 2019.5All doses in RA clinical trials included XELJANZ 1 mg, 3 mg, 5 mg, 10 mg, 15 mg, 30 mg BID; 10 mg or 20 mg QD; or 11 mg MR QD.710 mg BID is not licensed for RA2Adjudicated events5Composite MACE defined as any myocardial infarction, stroke, or cardiovascular death.5ORAL Surveillance study description1
Scroll left to view table
 
Design Phase IIIb/IV randomized, open-label, non-inferiority, postauthorization safety endpoint-driven study
Primary objective Evaluate the safety of tofacitinib at 2 doses (5 mg BID and 10 mg BID) compared with a TNFi in patients with RA who were 50 years of age or older and had at least 1 additional CV risk factor
Coprimary endpoints Adjudicated MACEa and adjudicated malignancies (excluding NMSC)
Statistical plan Determine whether the upper limit of the 95% CI for the primary comparison of the combined tofacitinib doses compared to TNFi exceeded the pre-specified non-inferiority criterion of 1.8
The approved dose of tofacitinib for RA is 5 mg BID.2MACE defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Patients who were treated with tofacitinib 10 mg BID were switched to tofacitinib 5 mg BID.Patients randomized to TNFi in North America, including United States, Puerto Rico, and Canada received adalimumab 40 mg q2w; in the rest of the world, those randomized to TNFi received etanercept 50 mg qw.Based on Cox proportional hazard model.NNH over a period of 5 years was the number of patients who would need to be treated for that duration with tofacitinib rather than a TNFi to result in one additional adverse event; calculations were performed post hoc. ORAL Surveillance: Baseline Characteristics
Scroll left to view table

  Treated patients
(N=4362)
Female, n (%) 3410 (78.2)
Median age, years (range) 60.0 (50.0-88.0)
Mean disease duration, years (SD) 10.4 (9.1)
Mean BMI, kg/m2 (SD) 29.8 (6.5)
Current/ex-smokers, n (%) 2103 (48.2)
Selected comorbidities, n (%)
    History of CHD 497 (11.4)
    History of diabetes mellitus 759 (17.4)
    History of hypertension 2878 (66.0)
    History of extra-articular disease  1605 (36.8)
ORAL Surveillance: Coprimary Endpoint Results for Adjudicated MACE and Adjudicated Malignancies (Excluding NMSC)1For adjudicated MACE and adjudicated malignancies (excluding NMSC), the prespecified noninferiority criterion was not met for the primary comparison of the combined tofacitinib doses to TNFiaAdjudicated MACE
  • The primary analyses included 135 patients with MACE
  • The most frequently reported MACE for tofacitinib was non-fatal myocardial infarction
Adjudicated malignancies (excluding NMSC)
  • The primary analyses included 164 patients with malignancies (excluding NMSC)
  • ​​​​​​​The most frequently reported malignancy with tofacitinib was lung cancer
  • A total time analysisc was used to assess the malignancy coprimary endpoint
Scroll left to view table


Tofacitinib
5 mg BID		 Tofacitinib 10 mg BID
(includes patients switched to 5 mg BID dose per Feb 2019 protocol amendment)		 Tofacitinib Doses Combined TNFi
Adjudicated MACE
No. of pts with first event/total no. (%) 47/1455 (3.2) 51/1456 (3.5) 98/2911 (3.4) 37/1451 (2.5)
No. of patient-years 5166.32 4871.96 10,038.28 5045.27
Incidence rate per 100 patient-year (95% CI) 0.91
(0.67, 1.21)		 1.05 
(0.78, 1.38)		 0.98 
(0.79, 1.19)		 0.73
(0.52, 1.01)
Hazard ratio for tofacitinib vs TNFi
(95% CI)d		 1.24
(0.81, 1.91)		 1.43
(0.94, 2.18)		 1.33
(0.91, 1.94)a
Noninferiority margin for primary comparison
(criterion not met; 1.94>1.8)
NNH (over 5-year period) vs TNFie 113 64


Adjudicated malignancies (excluding NMSC)
No. of pts with first event/total no. (%) 62/1455 (4.3) 60/1456 (4.1) 122/2911 (4.2) 42/1451 (2.9)
No. of patient-years 5491.48 5311.71 10,803.19 5482.30
Incidence rate per 100 patient-year (95% CI) 1.13
(0.87, 1.45)		 1.13
(0.86, 1.45)		 1.13
(0.94, 1.35)		 0.77
(0.55, 1.04)
Hazard ratio for tofacitinib vs TNFi
(95% CI)d 		 1.47
(1.00, 2.18)		 1.48
(1.00, 2.19)		 1.48
(1.04, 2.09)a
Noninferiority margin for primary comparison 
(criterion not met; 2.09>1.8)
NNH (over 5-year period) vs TNFie 55 55

The noninferiority criterion was not met for the primary comparison of the combined tofacitinib doses to TNFi since the upper limit of the 95% CI exceeded the pre-specified noninferiority criterion of 1.8. (ie, for MACE: 1.94>1.8, for malignancy: 2.09>1.8).Defined as the time from the first dose of a trial drug until the end of the risk period (ie, last contact date or last trial dose plus 60 days, whichever was earliest). ​​​​​​​Defined as the time from the first dose of a trial drug until the last contact date. The last contact date was the latest of the following: the start date of an AE, the end date of an AE, the date of the last trial visit, the withdrawal date, the telephone contact date, or the date of death. Based on Cox proportional hazard model.NNH over a period of 5 years was the number of patients who would need to be treated for that duration with tofacitinib rather than a TNFi to result in one additional adverse event; calculations were performed post hoc. ORAL Surveillance: Adverse Events of Special Interest1A 28-day on-treatment period analysis was used to assess AEs a 
Scroll left to view table
 
  Tofacitinib
5 mg BID		 Tofacitinib 10 mg BID (N=1456)
(includes patients switched to 
5 mg BID per Feb 2019 protocol amendment)		 TNFi (N=1451)
Serious AE, n (%) 351 (24.1) 390 (26.8) 306 (21.1)

AEs of special interest, n (%)
Hazard ratio for tofacitinib vs TNFi (95% CI)b
Serious infection 141 (9.7)
1.17 (0.92, 1.50)		 169 (11.6)
1.48 (1.17, 1.87)		 119 (8.2)
—
Adjudicated opportunistic infectionc 39 (2.7)
1.82 (1.07, 3.09)		 44 (3.0)
2.17 (1.29, 3.66)		 21 (1.4)
—
All herpes zosterd
(non-serious/serious)		 180 (12.4)
3.28 (2.44, 4.41)		 178 (12.2)
3.39 (2.52, 4.55)		 58 (4.0)
—
Adjudicated hepatic event 46 (3.2)
1.29 (0.83, 2.00)		 72 (4.9)
2.14 (1.43, 3.21)		 35 (2.4)
—
Adjudicated NMSC 31 (2.1)
1.90 (1.04, 3.47)		 33 (2.3)
2.16 (1.19, 3.92)		 16 (1.1)
—
Adjudicated pulmonary embolism 9 (0.6) 2.93
(0.79, 10.83)		 24 (1.6)
8.26 (2.49, 27.43)		 3 (0.2)
—
Adjudicated deep vein thrombosis  11 (0.8)
1.54 (0.60, 3.97)		 15 (1.0)
2.21 (0.90, 5.43)		 7 (0.5)
—
Adjudicated venous thromboembolism 17 (1.2) 1.66 (0.76, 3.63) 34 (2.3)
3.52 (1.74, 7.12)		 10 (0.7)
—
Adjudicated death from 
any cause		 26 (1.8) 1.49 (0.81, 2.74) 39 (2.7)
2.37 (1.34, 4.18)		 17 (1.2)
—
Defined as the minimum of the date of last contact or the date of the last dose of a trial treatment plus 28 days.​​​​​​​Based on Cox proportional hazard model.Also included are opportunistic herpes zoster and tuberculosis events.Included are herpes zoster adjudicated as an opportunistic infection and nonadjudicated herpes zoster events. Explore more Learn about the oral administration of XELJANZ See recommended dosing ACR=American College of Rheumatology; ACS=Acute Coronary Syndrome; ATE=arterial thromboembolism; BID=twice daily; CAD=Coronary Artery Disease; CABG=Coronary Artery Bypass Graft; CHD=Coronary Heart Disease; csDMARD=conventional synthetic disease-modifying antirheumatic drug; CV=cardiovascular; DSMB=Data Safety Monitoring Board; DVT=deep vein thrombosis; EMA=European Medicines Agency; HZ=herpes zoster; IR=inadequate response; JAKi=Janus kinase inhibitor; MACE=major adverse cardiovascular event; MI=Myocardial Infarction; MR=modified release; MTX=methotrexate; NMSC=nonmelanoma skin cancer; PsA=psoriatic arthritis; pt-yr=patient year; QD=once daily; qw=once a week; q 2 wk=every 2 weeks; RA=rheumatoid arthritis; TB=tuberculosis; TNF=tumor necrosis factor; UA =Unstable Angina; UC=ulcerative colitis; VTE=venous thromboembolism.Safety and Tolerability
EFFICACY

Want to learn about the rapid ACR20 results seen with XELJANZ for patients with RA?

 See RA data
EXPERIENCE

Find out more about the JAKi with the longest market experience in RA, PsA, UC

 See XELJANZ Experience
References:Ytterberg SR, Deepak L Bhatt DL, Mikuls T, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316-26. [and supplementary appendix]XELJANZ (tofacitinib citrate) Approved Product InformationWollenhaupt J, Lee E-B, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89. doi:10.1186/s13075-019-1866-2Data on file. Pfizer Inc., New York, NY.Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021;7:e001595. doi:10.1136/rmdopen-2021-001595Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400-1413.Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and psoriasis with 37 066 patient-years of tofacitinib exposure. [supplementary appendix]. RMD Open. 2021;7(2):1-36.

▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

WARNINGS 
XELJANZ should only be used if no suitable treatment alternatives are available in patients: 
  • with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past, long-time smokers) 
  • with malignancy risk factors (e.g. current malignancy or history of malignancy) 
  • who are 65 years of age and older. 

See PI for details, Section 4.4 Special Warnings and Precautions for Use: Mortality; Major Adverse Cardiovascular Events (including Myocardial Infarction); Thrombosis; Malignancy and Lymphoproliferative Disorder (excluding Nonmelanoma Skin Cancer [NMSC]); Skin Cancer and Use in the Elderly. 


Before prescribing, please review full Product Information available here.
 

PBS Information: Authority required for the treatment of adults with severe active rheumatoid arthritis and for adults with severe psoriatic arthritis and for adults with moderate-to-severe ulcerative colitis. Refer to the PBS Schedule for full authority information. This product is not listed on the PBS for juvenile idiopathic arthritis, juvenile psoriatic arthritis, or ankylosing spondylitis.

®Registered Trademark.
PP-XEL-AUS-1406 06/23.
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about Pfizer medicines and vaccines.

Sign inRegisterAccountSign Out

The site is intended for Australian healthcare professionals.

 

©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.

 

PP-UNP-AUS-0095 01/23.

You are now leaving Pfizer
You are leaving PfizerPro.
You may be directed to a third-party website.
Please note third-party websites are not controlled by Pfizer or subject to our privacy policy.
 
PP-UNP-AUS-0095 01/23.